查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861924

生物技術服務市場按服務類型、最終用戶、技術、應用和產品類型分類－2025-2032年全球預測

Biotechnology Services Market by Service Type, End User, Technology, Application, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生技服務市場將成長至 5,310.7 億美元，複合年成長率為 11.98%。

關鍵市場統計數據
基準年 2024 2146.9億美元
預計年份：2025年 2402.4億美元
預測年份 2032 5310.7億美元
複合年成長率 (%) 11.98%

簡要介紹生物技術服務產業，闡述技術創新、營運韌性和不斷變化的相關人員優先事項之間的相互作用。

生技服務產業正經歷加速變革時期期，其驅動力包括技術創新、不斷變化的監管要求以及產學研夥伴關係的深化。從基因測序到細胞療法研發，提供各類服務的機構正在建構更複雜的價值鏈，其中數據、可重複性和業務永續營運與科學專業知識同等重要。本文旨在為買方、供應商和投資者在評估服務能力和成長潛力時，提出需要考慮的策略重點。

本報告後續章節將揭示儀器設備、計算生物學和自動化生物製程的進步如何重新定義該領域的競爭優勢。我們將重點介紹服務供應商如何透過拓展服務範圍、投資數位化平台以及深化與合約研究機構和學術機構的合作來應對這些變化。透過將這些趨勢置於供應鏈壓力和不斷變化的監管環境這一更廣泛的背景下，本導言將為讀者理解後續的詳細分析奠定基礎。

基因組學、數位技術和生物製程創新正在融合，重塑服務模式，迫使服務提供者整合資料驅動的工作流程和可擴展的營運模式。

生技服務領域正經歷多重變革，這些變革正在重塑供應商的發展藍圖和買家的行為模式。首先，先進基因組學和分析技術的興起，正將傳統上各自獨立的任務整合到數據驅動的工作流程中。定序能力的提升、PCR自動化、質譜分析精度​​的提高以及單細胞分析技術的進步，正在提供更深入的生物學見解並縮短研究週期。因此，能夠將儀器與強大的生物資訊流程結合的公司正在獲得策略優勢，而買家也越來越重視能夠加速獲得洞察的端到端解決方案。

其次，細胞療法和生物製藥計畫的蓬勃發展正在推動生物製程和客製化細胞株開發領域的創新。自體和異體細胞療法的營運需求正在加速可擴展發酵、純化和封閉式生產系統的投資。第三，數位轉型——包括基於雲端的數據管理、實驗室資訊學和人工智慧驅動的分析——正在提升軟體和服務在服務組合中的核心地位。最後，不斷變化的監管要求以及對可重複性和資料來源日益成長的重視，正促使供應商加強品質體系建設、採用標準化通訊協定並深化與學術界和臨床相關人員的合作。這些因素共同推動了傳統化驗服務與整合式數位生物製程平台的融合，為下一階段的產業競爭與合作奠定了基礎。

評估近期關稅變化對營運、採購和策略的影響，以及對供應連續性和區域生產選擇的影響

2025年實施的關稅和貿易措施對生物技術服務供應商的採購、供應鏈規劃和定價動態產生了即時和間接的影響。短期來看，進口設備、試劑和特殊耗材關稅的提高增加了依賴跨境採購的機構的到岸成本。這迫使許多服務提供者重新考慮其供應商組合，加快對替代供應商的資格認證，並建立庫存緩衝以防止關鍵項目中斷。由於服務提供者需要在保持服務連續性的同時應對利潤壓力，這些調整也影響與客戶的合約談判。

從長遠觀點，關稅已經重塑了投資模式以及關於區域生產和本地化的策略決策。一些儀器製造商和試劑供應商已表示有意實現製造地多元化或發展區域中心，或許能降低貿易政策波動帶來的風險。同時，買家正在評估近岸外包方案，並尋求擁有穩健的多區域供應鏈的供應商。複雜的監管合規和海關程序增加了行政負擔，促使大型供應商投資建立專門的貿易合規部門和數位化採購平台。重點，這些貿易趨勢正在提升垂直整合服務供應商和提供包含軟體和本地支援的整合解決方案的公司的價值，因為這些模式減少了日常營運對跨境運輸的依賴。因此，相關人員需要在控制成本的需求與保持獲得最尖端科技和特種試劑的途徑之間尋求平衡。

透過全面的細分分析來制定策略定位，該分析按服務類型、最終用戶、技術、應用領域和產品類型確定能力優先順序。

透過深入的細分分析，我們能夠從服務類型、最終用戶、技術、應用和產品類型等方面揭示競爭壓力、能力差距和機會。在服務類型方面，隨著定序量和分析複雜性的增加，包含資料分析和軟體解決方案的生物資訊服務在價值提案中的重要性日益凸顯。能夠同時提供發酵和純化服務的生物加工供應商，更有能力支持需要規模化生產和嚴格品管的生物製藥和細胞治療計畫。細胞治療服務在同種異體和自體途徑中的演變凸顯了不同的需求。同種異體療法需要可擴展的生產能力和穩健的供應鏈，而自體療法則強調快速物流和個人化的流程控制。客製化細胞株開發（無論是哺乳動物細胞系還是微生物細胞系）是早期藥物發現和生產的基礎，將其與涵蓋生物製藥到小分子藥物發現的藥物發現服務相結合，並與PCR和測序等基因組學服務相結合，能夠產生協同效應。

從終端用戶的觀點來看，包括政府和大學實驗室在內的學術和研究機構持續推動方法學創新和早期檢驗，而生物技術公司（包括成熟企業和Start-Ups）則將這些進展轉化為商業化產品線。支持臨床和臨床前試驗的受託研究機構（CRO）擴大與服務供應商合作，以提供全面的開發項目。擁有多元化產品組合的製藥公司（從全球巨頭到中小企業）優先考慮能夠滿足嚴格監管要求並確保可預測交貨的合作夥伴。在技​​術細分方面，層析法和質譜等分析技術在品質保證和表徵方面的重要性日益凸顯，而從2D系統到3D培養的細胞培養技術對於確保轉化研究的有效性至關重要。包括次世代定序和PCR在內的基因組技術在藥物發現和診斷中仍然發揮著重要作用，而流式細胞技術和顯微鏡等成像技術則提供了重要的表現型資訊。應用驅動的差異化在以下方面體現得尤為明顯：以生物標記發現和伴隨診斷為重點的診斷工作流程；以應用主導和靶點識別為中心的藥物發現活動；涵蓋基礎研究到轉化​​研究的舉措項目；以及包含臨床前和臨床試驗準備的治療開發活動。最後，產品類型分析表明，諸如微孔板、試管、試劑和套件等耗材支援常規實驗室工作流程，而顯微鏡、定序儀和光譜儀等設備則需要高額的資本投資，生物資訊軟體和實驗室資訊學等軟體和服務則提供了將數據轉化為可操作見解的連接紐帶。

區域趨勢和能力叢集（美洲、歐洲、中東和非洲、亞太地區）對採購、業務連續性和協作網路產生影響

區域趨勢正在塑造競爭格​​局和投資重點，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，先進的基因組學基礎設施、成熟的生物技術生態系統和充裕的創業投資資金推動了服務創新加速發展，並促成了綜合服務中心的形成。該地區擁有密集的學術研究機構、成熟的生物技術公司和受託研究機構（CRO）網路，為夥伴關係和轉化研究提供了沃土。監管和報銷體係也影響診斷和治療服務的擴張速度，要求醫療服務提供者謹慎應對複雜的聯邦和州級法規。

在歐洲、中東和非洲地區（EMEA），關鍵學術機構和專業合約研究組織（CRO）集中在核心區域，而其他地區則在快速發展基礎設施和人才，形成多元化的能力格局。某些司法管轄區之間的監管協調促進了跨境合作，而地緣政治和供應鏈的考量則導致了籌資策略。相較之下，亞太地區是新興服務供應商的中心，這些服務提供者將生產規模、試劑生產和成本競爭力與日益成長的技術專長相結合。該地區各國政府都在投資基因組學、細胞療法和生物製造能力，買家也擴大從亞太地區的合作夥伴採購從常規耗材到先進服務的各種產品和服務。在所有地區，透過數位平台實現的互聯互通和跨境合作正在加強服務生態系統的全球性，即便各組織也在尋求區域韌性和本地化能力。

推動供應商選擇的策略重點和競爭優勢包括化驗服務的數位化平台整合和區域能力投資。

主要服務供應商之間的競爭主要集中在整合能力、拓展地理範圍和推動數位化。那些超越單一服務範疇，提供將實驗室操作與生物資訊學和實驗室資訊學相結合的整合工作流程的公司，透過簡化計劃管理和提升資料連續性，正吸引客戶的注意。對生物製程設施、定序和試劑區域中心等能力的策略性投資，體現了縮短前置作業時間和提高服務可靠性的決心。與學術機構和合約研究組織 (CRO) 的合作，進一步加強了創新管道和客戶推薦。

許多供應商透過垂直整合細胞療法生產、臨床級定序以及複雜生物製藥客製化細胞株開發等領域的專業化和針對性服務來實現差異化。同時，技術合作以及先進分析工具和人工智慧平台的授權許可，能夠加快數據解讀速度，並帶來更精準的預測性流程洞察。競爭優勢日益依賴服務品質、可靠的監管記錄以及可重複結果的驗證能力。那些能夠兼顧技術卓越性和商業性靈活性（靈活的合約結構、透明的資料管治和清晰的監管流程）的公司，更有可能維持長期的客戶關係。

經營團隊可透過數位整合、供應鏈韌性、夥伴關係、監管準備和員工技能提升來加強自身能力，採取切實可行的高優先級行動。

產業領導者應優先考慮一系列切實可行的舉措，以保持競爭優勢並創造成長機會。首先，投資於整合式數位平台，將儀器輸出與生物資訊學和實驗室資訊學連接起來，以縮短洞察週期並提高可重複性。這項措施應輔以人才發展計劃，以提昇科學家在資料科學和自動化工作流程方面的技能，確保各組織最大限度地效用新技術。其次，實現供應商網路多元化，並為關鍵試劑、耗材和設備建立地理冗餘，以減輕貿易中斷和關稅造成的成本波動的影響。

第三，與學術機構和合約研究組織 (CRO) 進行有針對性的合作，共同開發細胞療法和先進基因組學等高成長領域的能力。第四，加強監管和品管基礎設施，以支援快速進入臨床和診斷流程。將合規方面的專業知識融入企劃團隊，可以減少技術轉移階段的摩擦。第五，考慮採用模組化服務模式，根據專案的成熟度，選擇所需的單一服務或提供端到端的整合工作流程。最後，優先考慮採購和營運中的永續性和可追溯性，因為買家和監管機構越來越期望看到企業對道德採購和環境管理做出實際承諾。透過分階段推進這些工作，並將其與明確的營運績效和客戶滿意度指標結合，經營團隊可以將策略意圖轉化為可衡量的成果。

我們採用了嚴謹的混合方法，結合了相關人員訪談、文獻回顧、細分分析和區域地圖繪製，以得出可靠的、基於證據的結論。

本分析的調查方法結合了定性和定量技術，以確保結論是基於可靠的證據。主要研究包括對服務供應商高管、生物製藥和學術實驗室採購人員、採購主管以及監管專家進行結構化訪談，以獲取有關決策促進因素、營運限制和技術採用模式的第一手資訊。次要研究則整合了同行評審文獻、技術應用說明、監管指南和公司資訊披露，以闡明主要研究結果並檢驗觀察到的趨勢。

為了協調不同觀點並識別跨資訊來源的一致徵兆，我們進行了數據三角測量和交叉檢驗。我們針對服務線、最終用戶類型、技術平台、應用和產品類型進行了細分分析，以深入解讀能力差距和策略機會。該調查方法還納入了區域映射，以捕捉基礎設施和政策方面的地域差異。作為品質保證措施，我們進行了專家同儕審查和敏感性檢驗，以確保結論在不同的假設條件下都具有穩健性。這種混合方法為切實可行的建議提供了支持，並為策略決策奠定了基礎。

報告簡要摘要了主要發現，重點強調了技術和營運韌性以及協作策略在競爭優勢方面的整合作用。

摘要，隨著技術創新、監管日益複雜以及供應鏈波動性的共同作用，生物技術服務產業正在快速發展，供應商和買家的期望也隨之改變。能夠將實驗室運作與先進資訊技術相結合、投資於可擴展的生物加工能力並建立具有韌性的、地域分佈廣泛的供應鏈的機構，將更有機會取得成功。學術界、合約研究機構 (CRO) 和產業界之間的策略合作將加速轉化研究，並擴大新興治療和診斷方法的應用範圍。

展望未來，那些能夠兼顧技術卓越與營運規範（確保可重複性、合規性和準時交付）的供應商將贏得客戶的持續信任。同樣重要的是，供應商能夠根據客戶需求調整其經營模式，並在適當情況下提供模組化或全方位服務方案。透過落實這些優先事項，相關人員將能夠成功應對政策變革、資金限制和技術變革，同時提供現代生命科學研發所需的高品質服務。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用基因組和蛋白質體分析拓展個人化醫療服務，為每位患者制定最佳治療方案。
  • 引入高通量單細胞定序平台，以增強研究工作流程中的細胞異質性分析
  • 利用先進的連續生物製程技術，生物製藥合約開發和生產（CDMO）業務實現成長。
  • 在開發新型治療方法的過程中，人們越來越依賴 CRISPR 和基因編輯服務供應商進行精準的基因組編輯。
  • 一種整合多組體學資料的微生物組分析服務的出現，為發現腸道環境和疾病生物標記提供了支持。
  • 利用數位病理學和人工智慧驅動的影像分析解決方案，提高臨床試驗的診斷準確性和效率。
  • 合成生物學服務的興起使得快速細胞株設計和生物生產途徑最佳化成為可能。
  • 開發結合機器人技術和先進檢測技術的自動化高通量篩檢服務，用於候選藥物評估
  • 擴大細胞和基因治療契約製造服務，以滿足日益成長的個人化細胞治療需求
  • 將雲端基礎的資料管理和網路安全解決方案整合到生物技術服務平台中，以實現合規的研究合作

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按服務類型分類的生物技術服務市場

  • 生物資訊服務
    • 數據分析
    • 軟體解決方案
  • 生物製程
    • 發酵服務
    • 煉油服務
  • 細胞治療服務
    • 異體細胞療法
    • 自體細胞療法
  • 客製化細胞株開發
    • 哺乳動物細胞株
    • 微生物細胞株
  • 藥物發現
    • 生物製劑藥物發現
    • 小分子藥物發現
  • 基因組服務
    • PCR 服務
    • 定序服務

第9章 依最終用戶分類的生技服務市場

  • 學術研究機構
    • 政府研究機構
    • 大學研究所
  • 生技公司
    • 現有生技公司
    • Start-Ups公司
  • CRO（受託研究機構）
    • 臨床研究
    • 臨床前研究
  • 製藥公司
    • 大型製藥企業
    • 中小型製藥公司

第10章 按技術分類的生技服務市場

  • 分析技術
    • 層析法
    • 質譜分析
  • 細胞培養技術
    • 3D文化
    • QR 圖文化
  • 基因組學技術
    • 次世代定序
    • PCR技術
  • 成像技術
    • 流式細胞技術
    • 顯微鏡

第11章 生技服務市場（依應用領域分類）

  • 診斷
    • 生物標記發現
    • 伴隨診斷
  • 藥物發現
    • 先導藥物最適化
    • 目標識別
  • 研究
    • 基礎研究
    • 轉化研究
  • 治療研發
    • 臨床試驗
    • 臨床前試驗

第12章 依產品類型分類的生技服務市場

  • 消耗品
    • 板和管
    • 試劑和套件
  • 裝置
    • 顯微鏡
    • 序列器
    • 光譜儀
  • 軟體和服務
    • 生物資訊軟體
    • 實驗室資訊學

第13章 各地區的生技服務市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生技服務市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生技服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Laboratory Corporation of America Holdings
    • IQVIA Holdings Inc.
    • SGS SA
    • Agilent Technologies, Inc.
    • Eurofins Scientific SE
    • PerkinElmer, Inc.
    • Charles River Laboratories International, Inc.
    • WuXi AppTec Co., Ltd.
Product Code: MRR-521BAA36EA71

The Biotechnology Services Market is projected to grow by USD 531.07 billion at a CAGR of 11.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 214.69 billion
Estimated Year [2025] USD 240.24 billion
Forecast Year [2032] USD 531.07 billion
CAGR (%) 11.98%

A concise orientation to the biotechnology services sector describing the interplay of technological innovation operational resilience and evolving stakeholder priorities

The biotechnology services landscape is experiencing a period of accelerated change driven by technological innovation, shifting regulatory expectations, and evolving partnerships across industry and academia. Organizations providing services from genomic sequencing to cell therapy development are navigating a more complex value chain in which data, reproducibility, and operational resilience have become equally important to scientific expertise. This introduction frames the strategic priorities that buyers, providers, and investors must weigh when evaluating service capabilities and growth potential.

Over the coming chapters, the report unpacks how advances in instrumentation, computational biology, and automated bioprocessing are redefining what constitutes competitive advantage in the sector. It highlights how service providers are responding by expanding offerings, investing in digital platforms, and deepening collaborations with contract research entities and academic centers. By situating these dynamics within the broader context of supply chain pressures and regulatory evolution, the introduction prepares readers for the deeper analysis that follows.

How converging genomic, digital, and bioprocessing innovations are redefining service models and forcing providers to integrate data driven workflows with scalable operations

The biotechnology services landscape is being reshaped by several transformative shifts that are altering provider roadmaps and buyer behavior. First, the ascendancy of advanced genomic and analytical technologies is turning previously discrete tasks into data-driven workflows; sequencing throughput, PCR automation, mass spectrometry precision, and single-cell approaches are enabling richer biological insights and compressing timelines. Consequently, companies that integrate instrumentation with robust bioinformatics pipelines are gaining strategic advantage as buyers increasingly prioritize end-to-end solutions that reduce time to insight.

Second, the proliferation of cell therapy and biologics programs is forcing innovation across bioprocessing and custom cell line development. The operational demands of autologous and allogeneic cell therapies have spurred investment in scalable fermentation, purification, and closed-system manufacturing approaches. Third, the acceleration of digital transformation-cloud-enabled data management, lab informatics, and AI-driven analysis-has elevated software and services to a keystone role in service portfolios. Finally, changing regulatory expectations and increasing emphasis on reproducibility and data provenance are prompting providers to strengthen quality systems, adopt standardized protocols, and pursue deeper partnerships with academic and clinical stakeholders. Together, these shifts are driving convergence between traditional laboratory services and integrated digital-bioprocessing platforms, setting the stage for the next phase of industry competition and collaboration.

Assessing the cascading operational, procurement, and strategic consequences of recent tariff changes and their implications for supply continuity and regional production choices

The implementation of tariffs and trade measures in 2025 has introduced immediate and secondary effects across procurement, supply chain planning, and pricing dynamics for biotechnology service providers. In the short term, increased duties on imported instruments, reagents, and specialized consumables have elevated landed costs for organizations that rely on cross-border sourcing. This has prompted many providers to reexamine supplier portfolios, accelerate qualification of alternative vendors, and to increase inventory buffers to insulate critical programs from disruption. In turn, these adjustments have influenced contractual negotiations with clients as providers seek to manage margin pressure while maintaining service continuity.

Over a longer horizon, tariffs have reshaped investment patterns and strategic decisions around regional production and localization. Some instrument manufacturers and reagent suppliers have signaled intentions to diversify manufacturing footprints or to develop regional hubs, which could mitigate exposure to trade policy volatility. At the same time, buyers are evaluating nearshoring options and seeking suppliers with robust multi-region supply chains. Regulatory compliance and customs complexity have added administrative overhead, encouraging larger providers to invest in dedicated trade compliance functions and digital procurement platforms. Importantly, these trade dynamics have amplified the value of vertically integrated service providers and those that offer bundled solutions including software and local support, since such models reduce reliance on cross-border shipments for routine operations. As a result, stakeholders are balancing the need for cost control against the imperative to preserve access to best-in-class technologies and specialized reagents.

Comprehensive segmentation insights that reveal capability priorities across service types end users technologies applications and product categories to inform strategic positioning

Insightful segmentation analysis reveals where competitive pressures, capability gaps, and opportunity vectors lie across service types, end users, technologies, applications, and product types. Within service type, bioinformatics services-comprising data analysis and software solutions-are increasingly central to value propositions as sequencing volumes and analytic complexity rise. Bioprocessing providers that can deliver both fermentation and purification services are better positioned to support biologics and cell therapy programs that require scale and stringent quality controls. The evolution of cell therapy services across allogeneic and autologous pathways highlights divergent needs: allogeneic approaches demand scalable manufacturing and supply chain robustness while autologous workflows emphasize rapid logistics and individualized process control. Custom cell line development, whether mammalian or microbial, remains foundational for early discovery and production, and its integration with drug discovery services-spanning biologics and small molecule discovery-creates synergies when paired with genomic services such as PCR and sequencing.

From an end user perspective, academic and research institutes including government and university labs continue to drive methodological innovation and early-stage validation, while biotech companies-both established firms and startups-translate these advances into commercial pipelines. Contract research organizations supporting clinical and preclinical studies are increasingly collaborating with service providers to deliver comprehensive development programs. Pharmaceutical companies with diverse portfolios, including large global firms and mid-size and small pharmas, prioritize partners that can meet rigorous regulatory expectations and provide predictable delivery. Technology segmentation underscores the importance of analytical techniques like chromatography and mass spectrometry for quality and characterization, while cell culture technologies-ranging from two-dimensional systems to three-dimensional culture-are essential for translational relevance. Genomic technologies, including next generation sequencing and PCR, remain critical for discovery and diagnostics, and imaging technologies such as flow cytometry and microscopy provide indispensable phenotypic context. Application-driven differentiation is evident across diagnostic workstreams focused on biomarker discovery and companion diagnostics, drug discovery efforts centered on lead optimization and target identification, research initiatives spanning basic to translational studies, and therapeutic development activities that encompass both preclinical testing and clinical trial readiness. Finally, product type analysis shows that consumables like plates, tubes, reagents and kits underpin daily laboratory workflows, while instruments including microscopes, sequencers, and spectrometers represent high-value capital investments, and software and services such as bioinformatics software and lab informatics deliver the connective tissue that turns data into actionable insight.

Regional dynamics and capability clusters across the Americas Europe Middle East & Africa and Asia Pacific that influence sourcing operational resilience and collaborative networks

Regional dynamics are shaping competitive landscapes and investment priorities, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, advanced genomic infrastructure, a mature biotechnology ecosystem, and deep venture funding have driven rapid service innovation and the formation of integrated service hubs. This region benefits from a dense network of academic centers, established biotech firms, and contract research organizations, creating fertile ground for partnerships and translational initiatives. Regulatory agencies and reimbursement frameworks also influence the pace at which diagnostics and therapeutic services scale, and providers must navigate a complex patchwork of federal and state-level requirements.

Europe Middle East & Africa presents a mosaic of capabilities with leading academic institutions and specialized CROs concentrated in core hubs, while other areas are rapidly developing infrastructure and talent. Regulatory harmonization across certain jurisdictions has aided cross-border collaboration, though geopolitical factors and supply chain considerations create variability in procurement strategies. In contrast, Asia-Pacific has become a center for manufacturing scale, reagent production, and emerging service providers that combine cost competitiveness with growing technical expertise. Governments across the region are investing in genomics, cell therapy, and biomanufacturing capabilities, and buyers increasingly source both routine consumables and sophisticated services from Asia-Pacific partners. Across all regions, connectivity through digital platforms and cross-border collaborations is reinforcing the global nature of the services ecosystem even as organizations pursue regional resilience and localized capabilities.

Strategic company priorities and competitive differentiators that determine provider selection including integration of laboratory services digital platforms and regional capacity investments

Competitive dynamics among leading service providers are centered on capabilities integration, geographic footprint, and digital enablement. Companies that have expanded beyond single-service offerings to provide bundled workflows-combining laboratory execution with bioinformatics and lab informatics-are capturing client interest by simplifying project management and improving data continuity. Strategic investments in capacity, whether through new facilities for bioprocessing or regional hubs for sequencing and reagents, reflect a drive to reduce lead times and enhance service reliability. Partnerships with academic institutions and CROs further strengthen pipelines for innovation and client referrals.

Many providers are differentiating through targeted service verticalization, specializing in areas such as cell therapy manufacturing, clinical-grade sequencing, or bespoke cell line development for complex biologics. At the same time, technology partnerships and licensing arrangements for advanced analytical tools and AI platforms are enabling faster data interpretation and predictive process insights. Competitive positioning increasingly hinges on service quality, regulatory track record, and the ability to demonstrate reproducible outcomes. Firms that balance technical excellence with commercial agility-offering flexible contracting, transparent data governance, and clear regulatory pathways-are most likely to sustain long-term client relationships.

Practical and prioritized actions for executives to strengthen capabilities through digital integration supply chain resilience partnerships regulatory readiness and workforce upskilling

Industry leaders should prioritize a set of actionable initiatives to maintain competitive relevance and to unlock growth opportunities. First, invest in integrated digital platforms that connect instrument output to bioinformatics and lab informatics, thereby shortening insight cycles and improving reproducibility. This approach should be complemented by workforce development programs that upskill scientists in data science and automated workflows, ensuring organizations maximize the utility of new technologies. Second, diversify supplier networks and build regional redundancy for critical reagents, consumables, and instruments to mitigate the impact of trade disruptions and tariff-driven cost volatility.

Third, pursue targeted collaborations with academic centers and CROs to co-develop capabilities in high-growth areas such as cell therapy and advanced genomic assays. Fourth, enhance regulatory and quality infrastructures to support rapid entry into clinical and diagnostic pathways; embedding compliance expertise within project teams will reduce friction during translational phases. Fifth, explore modular service models that allow clients to select discrete capabilities or bundled end-to-end workflows depending on program maturity. Finally, prioritize sustainability and traceability in procurement and operations, as buyers and regulators increasingly expect demonstrable commitments to ethical sourcing and environmental stewardship. By sequencing these initiatives and aligning them with clear metrics for operational performance and client satisfaction, leaders can convert strategic intent into measurable outcomes.

A rigorous mixed methods approach combining stakeholder interviews literature synthesis segmentation analysis and regional mapping to ensure robust evidence based conclusions

The research methodology underpinning the analysis combined qualitative and quantitative techniques to ensure robust, evidence-based conclusions. Primary research included structured interviews with senior executives across service providers, buyers in biopharma and academic laboratories, procurement leads, and regulatory specialists, enabling direct insights into decision drivers, operational constraints, and technology adoption patterns. Secondary research synthesized peer-reviewed literature, technology application notes, regulatory guidance, and company disclosures to contextualize primary findings and to validate observed trends.

Data triangulation and cross-validation were applied to reconcile differing perspectives and to identify consistent signals across sources. Segmentation analysis was performed by dissecting service lines, end user types, technology platforms, applications, and product types, which allowed for granular interpretation of capability gaps and strategic opportunities. The methodology also incorporated regional mapping to capture geographic variations in infrastructure and policy. Quality assurance measures included peer review by subject matter experts and sensitivity checks to ensure that conclusions remained robust under alternative assumptions. This mixed-methods approach supports practical recommendations and provides a defensible basis for strategic decision-making.

Concise synthesis of the report findings emphasizing integration of technology operational resilience and collaborative strategies to secure competitive advantage

In summary, the biotechnology services sector is evolving rapidly as technological innovation, regulatory complexity, and supply chain dynamics converge to redefine provider and buyer expectations. Success will favor organizations that integrate laboratory execution with advanced informatics, invest in scalable bioprocessing capabilities, and build resilient, regionally diversified supply chains. Strategic collaborations across academia, CROs, and industry will accelerate translational work and expand access to emerging therapeutic and diagnostic opportunities.

Looking forward, providers that balance technical excellence with operational discipline-ensuring reproducibility, compliance, and timely delivery-will win sustained client trust. Equally important will be the ability to adapt commercial models to client needs, offering modular services or full-service programs as appropriate. By executing against these priorities, stakeholders can better navigate policy shifts, capital constraints, and technological disruption while delivering the high-quality services that modern life sciences research and development demand.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of personalized medicine services leveraging genomic and proteomic profiling for tailored therapeutic strategies
  • 5.2. Adoption of high-throughput single-cell sequencing platforms to enhance cellular heterogeneity analysis in research workflows
  • 5.3. Growth of contract development and manufacturing of biologics with advanced continuous bioprocessing capabilities
  • 5.4. Increasing reliance on CRISPR and gene editing service providers for precision genome engineering in novel therapeutic development
  • 5.5. Emergence of microbiome analysis services integrating multi-omics data to support gut health and disease biomarker discovery
  • 5.6. Utilization of digital pathology and AI-driven image analysis solutions to improve diagnostic accuracy and throughput in clinical trials
  • 5.7. Rise of synthetic biology service offerings enabling rapid cell line engineering and pathway optimization for bioproduction
  • 5.8. Development of automated high-throughput screening services combining robotics and advanced assay technologies for drug candidate evaluation
  • 5.9. Expansion of cell and gene therapy contract manufacturing services to meet growing demand for personalized cell-based treatments
  • 5.10. Integration of cloud-based data management and cybersecurity solutions in biotech service platforms for compliant research collaboration

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biotechnology Services Market, by Service Type

  • 8.1. Bioinformatics Services
    • 8.1.1. Data Analysis
    • 8.1.2. Software Solutions
  • 8.2. Bioprocessing
    • 8.2.1. Fermentation Services
    • 8.2.2. Purification Services
  • 8.3. Cell Therapy Services
    • 8.3.1. Allogeneic Cell Therapy
    • 8.3.2. Autologous Cell Therapy
  • 8.4. Custom Cell Line Development
    • 8.4.1. Mammalian Cell Line
    • 8.4.2. Microbial Cell Line
  • 8.5. Drug Discovery
    • 8.5.1. Biologics Discovery
    • 8.5.2. Small Molecule Discovery
  • 8.6. Genomic Services
    • 8.6.1. PCR Services
    • 8.6.2. Sequencing Services

9. Biotechnology Services Market, by End User

  • 9.1. Academic And Research Institutes
    • 9.1.1. Government Labs
    • 9.1.2. University Labs
  • 9.2. Biotech Companies
    • 9.2.1. Established Biotech
    • 9.2.2. Startups
  • 9.3. Contract Research Organizations
    • 9.3.1. Clinical Research
    • 9.3.2. Preclinical Research
  • 9.4. Pharmaceutical Companies
    • 9.4.1. Big Pharma
    • 9.4.2. Mid Size And Small Pharma

10. Biotechnology Services Market, by Technology

  • 10.1. Analytical Techniques
    • 10.1.1. Chromatography
    • 10.1.2. Mass Spectrometry
  • 10.2. Cell Culture Technologies
    • 10.2.1. Three D Culture
    • 10.2.2. Two D Culture
  • 10.3. Genomic Technologies
    • 10.3.1. Next Generation Sequencing
    • 10.3.2. PCR Technology
  • 10.4. Imaging Technologies
    • 10.4.1. Flow Cytometry
    • 10.4.2. Microscopy

11. Biotechnology Services Market, by Application

  • 11.1. Diagnostic
    • 11.1.1. Biomarker Discovery
    • 11.1.2. Companion Diagnostics
  • 11.2. Drug Discovery
    • 11.2.1. Lead Optimization
    • 11.2.2. Target Identification
  • 11.3. Research
    • 11.3.1. Basic Research
    • 11.3.2. Translational Research
  • 11.4. Therapeutic Development
    • 11.4.1. Clinical Trials
    • 11.4.2. Preclinical Testing

12. Biotechnology Services Market, by Product Type

  • 12.1. Consumables
    • 12.1.1. Plates And Tubes
    • 12.1.2. Reagents And Kits
  • 12.2. Instruments
    • 12.2.1. Microscopes
    • 12.2.2. Sequencers
    • 12.2.3. Spectrometers
  • 12.3. Software And Services
    • 12.3.1. Bioinformatics Software
    • 12.3.2. Lab Informatics

13. Biotechnology Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biotechnology Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biotechnology Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Laboratory Corporation of America Holdings
    • 16.3.4. IQVIA Holdings Inc.
    • 16.3.5. SGS SA
    • 16.3.6. Agilent Technologies, Inc.
    • 16.3.7. Eurofins Scientific SE
    • 16.3.8. PerkinElmer, Inc.
    • 16.3.9. Charles River Laboratories International, Inc.
    • 16.3.10. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOTECHNOLOGY SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOTECHNOLOGY SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOTECHNOLOGY SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THREE D CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THREE D CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THREE D CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THREE D CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THREE D CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THREE D CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TWO D CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TWO D CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TWO D CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TWO D CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TWO D CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TWO D CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)

TA